Project Leader – Endosomal Signalling (Targeting Endosomes for Treatment of Pain)
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences
Dr. Nicholas Veldhuis is Research Fellow in the Drug Discovery Biology Theme at Monash University. His work focuses on identifying and characterising new drug targets (receptors, ion channels, signalling proteins) that contribute to pain and inflammation, and developing novel drug delivery systems (lipid anchors and nanoparticles). He is the project leader for “Endosomal drug delivery systems: Targeting pain at the source”.
Nicholas has expertise in cell biology, live cell protein trafficking, protein expression/purification, cell signalling, and development of novel drug delivery systems for selective inhibition of pain signalling GPCRs.
Dr Veldhuis is performing research that aligns with the following Signature Projects:
|Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief||2017||Jensen DD, Lieu T, Halls ML, Veldhuis NA, Imlach WL, Mai QN, Poole DP, Quach T, Aurelio L, Conner J, Herenbrink CK, Barlow N, Simpson JS, Scanlon MJ, Graham B, McCluskey A, Robinson PJ, Escriou V, Nassini R, Materazzi S, Geppetti P, Hicks GA, Christie MJ, Porter CJH, Canals M, Bunnett NW|
|G Protein-Coupled Receptors: Dynamic Machines for Signaling Pain and Itch||2015||Geppetti P, Veldhuis NA, Lieu T, Bunnett NW.|
|P2Y1 Receptor Activation of the TRPV4 Ion Channel Enhances Purinergic Signaling in Satellite Glial Cells||2015||Rajasekhar P, Poole DP, Liedtke W, Bunnett NW, Veldhuis NA|
|Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome||2015||Cenac N, Bautzova T, Le Faouder P, Veldhuis NA, Poole DP, Rolland C, Bertrand J, Liedtke W, Dubourdeau M, Bertrand-Michel J, Zecchi L, Stanghellini V, Bunnett NW, Barbara G, Vergnolle N.|
|The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation||2015||Veldhuis NA, Poole DP, Grace M, McIntyre P, Bunnett NW.|